Subject: Current and future applications - view Table of Contents
From: "Systems Biology Report" <[email-masked]>
To: "Strom" <[email-masked]>
Date: Wed, 4 Jun 2008 16:19:00 -0400

CHI's Insight Pharma Report        JUST PUBLISHED - MAY 2008
Systems Biology: A Disruptive Technology
This report focuses on the current and future applications of Systems Biology in drug discovery, specifically in 
pinpointing optimal individual targets, and combinations of targets, to overcome metabolic pathway redundancies, 
leading to efficacious and safe products. 
Report Brochure      

Overview
Sample Pages
TABLE OF CONTENTS
Chapter 1
INTRODUCTION
1.1. Scope and Content of This Report
1.2. Historical Perspective
1.3. Defining Systems Biology
Chapter 2
TECHNOLOGICAL ASPECTS OF SYSTEMS BIOLOGY
2.1. Bioanalytical Technologies
  Academic Perspective: Institute for Systems Biology
  Commercial Perspective: BG Medicine
2.2. Regulatory Mechanisms and Organization
  DNA-Protein Binding: ChIP-on-Chip Analysis
  DNA Methylation
  MicroRNAs
2.3. Bioinformatics Technologies
  Pathway Analysis
        Databases
        Commercial Software Systems
  Cell and Disease Modeling
        Genstruct
        Entelos
        Gene Network Sciences
2.4. Summary
Chapter 3
BASIC RESEARCH IN SYSTEMS BIOLOGY
3.1. Network-Based Models and Simulations
  Types of Biological Networks
  Transcriptomic/Genetic Variation Approach
  Combination Drug Therapy
3.2. Protein Networks
  Yeast Two-Hybrid and Related Technologies
  Metabolic Interaction Networks
  Databases
  Systems Biology Research Approaches
3.3. An Emerging Paradigm for Viewing Health and Disease
  Diseaseome
  Genotyping/Gene Expression Combinations in Biological Network Construction
  Implications of Systems Biology for Clinical Medicine
  Systems Biology Approach for Cancer Research
Chapter 4
APPLIED RESEARCH IN SYSTEMS BIOLOGY
4.1. Impacts of Systems Biology on Specific Disease Areas
  Cancer
        Acceptance of Systems Biology by Big Pharma 
       Network-Based Cancer Research
  Neurological Diseases
  Cardiovascular Diseases
  Metabolic Disorders
Chapter 5
MARKET DYNAMICS
5.1. Approaches of Small-Company Players X
  Ariadne Genomics
  BG Medicine
  BioSeek
  Connexios
  Entelos
  Gene Network Sciences
  GeneGo
  Genetics Squared
  Genomatica
  Genstruct
  Ingenuity Systems
  Optimata
  Physiomics
  Protein Lounge
5.2. Approaches of Selected Drug Discovery and Development Organizations
  Cellicon Biotechnologies
  CombinatoRx
  e-Therapeutics
  Merck
  Merrimack Pharmaceuticals
  Pfizer
  SU Biomedicine
5.3. Systems Biology Deals
5.4. Insight Pharma Reports Systems Biology Survey: Results and Comments
Chapter 6
CONCLUSIONS AND FUTURE PROSPECTS
6.1. Challenges for Systems Biology in Drug Discovery
6.2. Possible Solutions to Advancing Medical and Pharmacological Knowledge via Systems Biology
6.3. Systems Biology as a Disruptive Technology
6.4. Future Prospects
Chapter 7
EXPERT INTERVIEWS
David de Graaf, PhD
Director of Systems Biology, Pfizer, Research Technology Center, Cambridge, MA
Brian Edmonds, PhD
Research Advisor, Integrative Biology and Global External Research, Lilly Research Laboratories, Indianapolis, IN
Colin Hill
CEO, President, Chairman, and Co-Founder, Gene Network Sciences, Cambridge, MA
David Lester, PhD
President and Founder, ITHW, Inc., Morristown, NJ
Stephen Naylor, PhD
Chairman, CEO, and Co-Founder, Predictive Physiology and Medicine (PPM), Bloomington, IN
References
Company Index with Web Addresses
Questions? Contact Rose LaRaia at [email-masked], 781-972-5444

CHI Insight Pharma Reports | a division of Cambridge Healthtech Institute 
250 First Avenue, Suite 300 | Needham, MA 02494
InsightPharmaReports.com
Your Life Science Network - CHI's Integrated Portfolio Includes:
Cambridge Healthtech Institute Conferences | Cambridge Healthtech Media Group
Insight Pharma Reports | Custom Market Research | Lead Generation Programs
Marketing Services & Meeting Planning | Clinical Educational Services
CHIcorporate.com  |  www.CHImediagroup.com | BarnettInternational.com
This email communication is for commercial purposes. if it is not of interest to you, please disregard and we 
apologize for any inconvenience this may have caused.  
To prevent further emails, click here or go to www.chiresource.com/rmv.asp